Active, not recruitingPhase 2NCT04925544

Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

Studying Epstein-Barr Virus-associated carcinoma

Last synced from ClinicalTrials.gov May 13, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Stanford University
Principal Investigator: A. Dimitrios Colevas
Stanford Universiy
Intervention: VK-2019(drug)
Enrollment: 13 enrolled
Eligibility: 18 years · All sexes
Timeline: 2022 – 2027

Study locations (1)

Stanford University, Stanford, California, United States

Collaborators

National Institutes of Health (NIH) · National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04925544 on ClinicalTrials.gov

Other trials for Epstein-Barr Virus-associated carcinoma

Additional recruiting or active studies for the same condition.

RECRUITINGNANCT06682442
Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
University of California, San Francisco

See all trials for Epstein-Barr Virus-associated carcinoma →

← Back to all trials